ORIGINAL ALFLUTOP BIOTEHNOS
Drug Classification: Chondroprotector
PRICE: 70 EURO / box 10 Vials
|
Payments accepted:
1. Secure
Bank Transfer Wire
2.
Transferwise
3. Western
Union Online
Shipping outside of
Europe costs 50USD$
(tracking code included).
|
For customers from USA and CANADA there are no restrictions from FDA or U.S/CANADA custom to import our Authentic ALFLUTOP Biotehnos
Alflutop is the trademarked name of a product produced by the
pharmaceutical company Biotehnos. The Alflutop produced by this company
contains sea fish bioactive concentrate, which itself contains low molecular
mass peptides, mucopolysaccharides, and amino acids. Also included are trace
elements including zinc, copper, sodium, calcium, iron, and magnesium. Most
often the compound is packaged in one milliliter amps which each contain ten
milligrams of sea fish bioactive concentrate, as well as phenol which possesses
anesthetic properties as well as acting as a preservative.
The medical
use of Alflutop is primarily for the treatment of degenerative joint disorders
such as tendonitis, ankylopoietic spondilitis, bursitis, spinal disc injuries
and arthritis-related disorders (1). Obviously these are the same uses that
bodybuilders and strength athletes will want to utilize Alflutop for as well.
Alflutop
works in numerous ways to help stop tissue damage from happening in joints,
while also repairing tissues that have already been damaged. This occurs via
cartilage regeneration and a reduction in free radical damage within joint
tissues. As well, the contents of Alflutop help to inhibit overproduction of
hyaluronidase, an enzyme that catalyzes the breakdown of hyaluronic acid in the
tissues of the body. Excessive production of this enzyme can lead to serious
damage within joints. Alflutop will also help to restore and maintain
homeostasis within chondrocytes, the structures responsible for the production
and maintenance of the extracellular matrix of cartilage.
Along with
the injectable version of Alflutop, Biotehnos also produces a topical ointment
as well as a suppository form of the compound. However both of these forms of
the drug will of course be less efficient as a delivery method of the compound
and less effective. The injectable version of Alflutop is also the more
commonly found form of the compound. For these reasons, the majority of users
will want to administer the drug via injections.
Use/Dosing
Due to the
active life of the compound, frequent dosing is required. For the most part,
most users find that injecting one amp, 10mgs sea fish bioactive concentrate or
one milliliter in volume, every day or every other day for a period of
approximately twenty-one days will bring substantial relief in the majority of
their symptoms as they relate to joint discomfort and/or damage. However this
protocol has basically been devised by way of anecdotal information passed on
from one user to another. In clinical trials the length of administering the
drug has ranged from less then seven days to as long as several months. It was
found that various lengths of time were needed to treated individuals and these
were based on several factors including the amount of damage/trauma that was
inflicted upon the joint(s), how well the individual reacted to the drug, and
how much physical activity and recuperation methods the individuals used in
conjunction with the drug treatment, among others. For this reason, no set
standard needs to be adhered to when using Alflutop and the length of use
should be determined by the results achieved with the compound.
The
injectable version of Alflutop is administered via intramuscular injections. It
seemingly does not matter which muscles that the compound is injected into as
it will affect all of the joints of the user equally. There is no additional
benefit to administering the drug into the area of the injury or trauma. This,
along with the frequency of the injections, would allow the user to spread the
injections throughout several muscle groups so as not to cause undue irritation
to the muscles that the compound is being administered to.
In terms of
use for females, it appears that the same dosages can be translated to women as
they are for men. No real changes to the volume or frequency of the dosing of
the drug need to be made, with no increase of severity or frequency of
potential side effects being seen in women.
Like the
duration of the administration of the drug, the frequency with which a user
chooses to cycle the compound seemingly will not be hindered by side effects
either. If one chooses to run Alflutop several times within a short period of
time, this appears to be beneficial. In fact in the case of rheumatoid
arthritis, this is the protocol for treatment using the drug in many cases (2).
However anecdotally users have reported only needing to use the compound once
or twice for years at a time and have never had a reoccurrence of their
symptoms. Of course, a number of factors could also contribute to this, most
notably being that most would not subject themselves to the activity that had
caused the initial damage or trauma in the first place.
Risks/Side
Effects
From the
available research that has thus far been conducted it seems that Alflutop is
well tolerated by nearly all subjects that have received it as treatment. It is
also important to note that the vast majority of this research has been
completed using elderly patients due to the research primarily concerning
itself with use of the drug in those individuals who suffer from rheumatoid
arthritis, among other conditions. This is important since many of these older
patients may suffer from other age related diseases and/or conditions. From the
research that has been conducted it appears that Alflutop has had not negative
effects on those patients suffering from heart conditions, gastrointestinal
distress/diseases or diseases of the thyroid (2, 3). Obviously these findings
should also presumably hold true for younger, healthier individuals.
The only
real negative side effects associated with the administration of Alflutop are
some reports of irritation related to the frequent injections. Some
post-injection pain was noted by some patients while others tolerated the
frequent injections well. However no major complications related to the
injections were reported in the available research and literature related to
Alflutop.
References
1. Noskov
SM, Fetelego OI, Krasivina IG, Dolgova LN. [Alflutop in local therapy of
shoulder periarthritis] Ter Arkh. 2005;77(8):57-60.
2. Svetlova
MS, Ignat'ev VK. [Use of alflutop in the treatment of patients with
osteoarthrosis] Klin Med (Mosk). 2004;82(6):52-5.
3. Taran AI,
Puzanova OG, Lapenko OIe, Sol's'kyi VI, Samoilova SM. [Experience gained with
the use of local administration of medicinal remedies in rheumatic diseases]
Lik Sprava. 2001 Sep-Dec;(5-6):182-5.
No comments:
Post a Comment
Note: only a member of this blog may post a comment.